Advertisement
Screener

Humacyte, Inc. (HUMA) Cash Flow Breakdown

Humacyte, Inc. Cash Flow Breakdown

Cash flow breakdown shows where Humacyte, Inc.'s cash came from and where it went: from running the business, from investing (buying or selling equipment, companies and investments) and from financing (borrowing, paying back loans, buying back shares, paying dividends). One row per year or quarter. A minus sign means cash went out. Financing is shown line by line: buybacks, dividends, debt paid back, new debt and the rest. All amounts are the filed figures for that period.

  • Fiscal year ended 2025-12-31: from running the business, $105.04M went out.
  • Fiscal year ended 2025-12-31: from investing, $884.00K went out.
  • Fiscal year ended 2025-12-31: from financing, $61.49M came in.
  • Fiscal year ended 2025-12-31: change in cash, $44.44M went out.

A minus sign means cash went out. * = worked out from the filed year-to-date figures (hover to see how); greyed = already counted inside another line.

Each year (12 month)

Fiscal year endRunning the businessFrom investingDebt paid backNew debtCommercial paperNew shares soldNot split outChange in cash
2025-12-31-$105.04M-$884.00K-$88.00M$39.78M$61.00K$109.64M*-$44.44M
2024-12-31-$98.12M-$1.57M$0.00*$0.00$1.51M$112.67M*$14.49M
2023-12-31-$73.31M-$173.00K-$310.00K$566.00K$4.25M*-$68.97M
2022-12-31-$71.13M$4.84M$0.00$535.00K-$1.98M*-$67.73M
2021-12-31-$81.19M-$8.22M$0.00$242.40M$24.58M*$177.57M
2020-12-31-$55.57M-$268.00K$3.25M$0.00-$1.20M*-$53.78M

Each quarter (3 month)

Quarter endRunning the businessFrom investingDebt paid backNew debtNew shares soldNot split outChange in cash
2026-06-30-$22.06M*-$104.00K*$30.00K*$53.50M*
2026-03-31-$25.10M-$175.00K$0.00$23.32M*-$1.96M
2025-12-31-$26.12M*-$39.00K*$5.00K*$57.17M*
2025-09-30-$23.90M*-$49.00K*$0.00*-$44.59M*
2025-06-30-$26.41M*-$568.00K*$0.00*$2.17M*
2025-03-31-$28.60M-$228.00K$56.00K$46.68M*$17.91M
2024-12-31-$26.58M*-$63.00K*$0.00*$227.00K*$50.78M*
2024-09-30-$22.91M*-$934.00K*$0.00*$495.00K*
2024-06-30-$21.29M*-$184.00K*$0.00*
2024-03-31-$27.35M-$391.00K$43.40M$19.40M*$35.06M
2023-12-31-$19.05M*-$150.00K*$0.00*$253.00K*
2023-09-30-$13.01M*-$493.00K*$0.00*$99.00K*-$863.00K*
2023-06-30-$22.60M*$1.62M*-$300.00K$0.00*$6.32M*
2023-03-31-$18.64M-$1.15M$0.00-$20.20M
2022-12-31-$18.96M*$5.21M*$0.00*$306.00K*
2022-09-30-$16.80M*-$211.00K*$0.00*$217.00K*
2022-06-30-$16.57M*-$134.00K*$11.00K*
2022-03-31-$18.80M-$22.00K$1.00K-$19.28M
2021-12-31-$21.45M*-$8.04M*$2.00K*$6.54M*
2021-09-30-$30.52M*-$83.00K*$360.00K*$241.72M*
2021-06-30-$14.68M*-$63.00K*$30.00K*-$946.00K*
2021-03-31-$14.54M-$29.00K$206.00K$19.07M*$4.70M
2020-12-31-$227.61K*$0.00*$0.00*$0.00*
2020-09-30-$18.05K-$100.00M$25.00K$101.31M*$1.32M

Similar stocks

Stock NameCountryMarket CapPE Ratio
Outlook Therapeutics, Inc. (OTLK)United States$0.162B-4.90
Acumen Pharmaceuticals, Inc. (ABOS)United States$0.162B-1.83
Tenaya Therapeutics, Inc. (TNYA)United States$0.140B-1.60
Voyager Therapeutics, Inc. (VYGR)United States$0.173B-1.99
PRECISION BIOSCIENCES INC (DTIL)United States$0.175B-3.95
Caribou Biosciences, Inc. (CRBU)United States$0.134B-1.79
Armata Pharmaceuticals, Inc. (ARMP)United States$0.132B
Neumora Therapeutics, Inc. (NMRA)United States$0.132B-1.48
enGene Therapeutics Inc. (ENGN)$0.129B-0.92
Coherus Oncology, Inc. (CHRS)United States$0.182B-1.63